467P - The prognostic value of Serum Cripto-1 in patients with non-small cell lung

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Rasha Haggag
Citation Annals of Oncology (2016) 27 (suppl_9): ix139-ix156. 10.1093/annonc/mdw594
Authors R.M. Haggag1, S. El-Shorbagy1, H.F. Ebian2, H.A. Labib3
  • 1Medical Oncology, Zagazig University Faculty of Medicine, 44519 - Zagazig/EG
  • 2Clinical Pathology, Zagazig University Faculty of Medicine, 44519 - Zagazig/EG
  • 3Clinical Pathology, Zagazig University Faculty of Medicine, 445109 - Zagazig/EG



Cripto-1 (CR-1) is a member of the epidermal growth factor-cripto FRL1 cryptic (EGF-CFC) family. It plays an important role in tumorigenesis by promoting cell proliferation, survival, migration, invasion and tumor angiogenesis. CR-1 is over-expressed in lung cancer tissues, and the levels of CR-1 expression are associated with the prognosis.


To explore the diagnostic and prognostic value of serum CR-1 levels in patients with NSCLC, Serum CR-1, VEGF, and CRP concentrations were measured using enzyme-linked immunosorbent assay.


Our study enrolled 91 non-small cell lung cancer (NSCLC) lung cancer patients (19 females and 75 males), and 31as control subjects (9 females and 22 males) from December 2013 through November 2015. Sex- and age-matched healthy volunteers were enrolled in the same period (P = 0.2 and 0.08, respectively). Patients with lung cancer had higher serum CR-1 levels than the control group (3.7± 1.03 ng/mL vs. 1.08 ± 0.38 ng/mL, p 


Measurement of serum CR-1 and VEGF levels can be considered as useful promising diagnostic and prognostic markers for NSCLC patients.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.